公开(公告)号：US10240133B2

公开(公告)日：2019-03-26

申请号：US15498493

申请日：2017-04-27

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Rony Seger ,  Alexander Plotnikov

IPC: A61K38/12 ,  C12N9/12 ,  A61K47/64 ,  A61K38/00

Abstract: An isolated peptide being no longer than 20 amino acids comprising a sequence at least 95% homologous to the sequence GQLNHILGILGX1PX2QED (SEQ ID NO: 4), wherein X1 and X2 are any amino acid, the peptide being capable of preventing extracellular signal-regulated kinase1/2 (ERK) translocation into the nucleus.

公开(公告)号：US10188679B2

公开(公告)日：2019-01-29

申请号：US14898732

申请日：2014-05-22

Applicant: Yeda Research and Development Co. Ltd

Inventor： Michal Eisenbach-Schwartz ,  Ester Yoles ,  Inbal Benhar Bar-On

IPC: A61K35/17 ,  C12N5/078 ,  A61K35/15 ,  A61K39/00 ,  C12N5/0786 ,  A61K9/00 ,  A61K35/12

Abstract: A monocyte subpopulation having a low relative amount, or substantially devoid, of CD3+ cells, CD19+ cells, CD56+ cells and optionally CD16+ cells is provided, wherein the monocyte subpopulation is for use in inhibition of neuronal degeneration, protection of neurons from glutamate toxicity or promotion of nerve regeneration in the retina or optic nerve, wherein the retina or optic nerve is damaged by a disease, disorder or condition of the eye, or for treatment of an inflammatory disease, disorder or condition of the eye.

公开(公告)号：US20190022198A1

公开(公告)日：2019-01-24

申请号：US16145641

申请日：2018-09-28

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Michal Eisenbach-Schwartz ,  Nir Friedman ,  Kuti Baruch ,  Gilad Kunis ,  Liora Cahalon ,  Neta Rosenzweig ,  Aleksandra Deczkowska

IPC: A61K39/00 ,  A61K45/06 ,  A61K38/21 ,  C12N5/0783 ,  C07K16/28 ,  A61K35/17

Abstract: A method for treating a disease, disorder, condition or injury of the Central Nervous System (CNS) in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of an active ingredient, such as a non-encephalitogenic or weakly encephalitogenic combination of a Th1 adjuvant and a CNS-specific antigen, causing activation of the choroid plexus of said subject and maintaining said activation by reducing immunosuppression and establishing Th1-type immune response at the choroid plexus thus allowing either anti-inflammatory immune cells or immune cells which acquire a healing phenotype at the cerebrospinal fluid to pass through the choroid plexus, and accumulate at a site of damage in the CNS caused by said disease, disorder, condition or injury is provided.

公开(公告)号：US20190002609A1

公开(公告)日：2019-01-03

申请号：US16064498

申请日：2016-12-22

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Jacob KLEIN ,  Weifeng LIN ,  Ronit GOLDBERG

IPC: C08F130/02 ,  A61K9/127 ,  A61K9/00 ,  C07F9/10

CPC classification number: C08F130/02 ,  A61K9/0019 ,  A61K9/0051 ,  A61K9/08 ,  A61K9/1273 ,  A61K47/6909 ,  A61P19/02 ,  C07F9/106 ,  C08F2438/01

Abstract: A polymeric compound is disclosed herein, having the general formula I: wherein m, n, X, Y, Z and L are as defined herein. Further disclosed herein are lipid bilayers comprising at least one bilayer-forming lipid and the aforementioned polymeric compound, and liposomes comprising such a bilayer, as well as methods, uses and compositions utilizing such bilayers and/or liposomes for reducing a friction coefficient of a surface and/or for inhibiting biofilm formation.

公开(公告)号：US10155933B2

公开(公告)日：2018-12-18

申请号：US14417559

申请日：2013-07-29

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Arren Bar-Even ,  Ron Milo ,  Elad Noor ,  Oren Yishai

IPC: C12N9/02 ,  C12N9/00 ,  C12N15/52 ,  C12P7/40 ,  C12M1/42 ,  C12N9/06 ,  C12N9/78 ,  C12N13/00

Abstract: An isolated microorganism that expresses enzymes of the reductive glycine pathway is disclosed. The microorganism is capable of converting formate to pyruvate or glycerate via the formation of glycine and serine. Methods of generating same are further described.

公开(公告)号：US20180318612A1

公开(公告)日：2018-11-08

申请号：US15772065

申请日：2016-10-27

Applicant: Yeda Research and Development Co., Ltd.,

Inventor： Eldad TZAHOR ,  Elad BASSAT

IPC: A61P9/10 ,  C12N5/077 ,  C07K14/47

CPC classification number: A61P9/10 ,  A61K38/1709 ,  A61L27/54 ,  A61L2300/252 ,  C07K14/4725 ,  C12N5/0657 ,  C12N2501/998

Abstract: An Agrin peptide which induces proliferation of cardiomyocytes for treating a heart disease is provided.

公开(公告)号：US20180296675A1

公开(公告)日：2018-10-18

申请号：US15924039

申请日：2018-03-16

Applicant: Memorial Sloan Kettering Cancer Center ,  Yeda Research and Development Co., Ltd. at the Weizmann Institute of Science

Inventor： Jonathan COLEMAN ,  Philip A. WATSON ,  Kwanghee KIM ,  Avigdor SCHERZ

IPC: A61K41/00 ,  A61P35/00 ,  A61K38/08 ,  A61K31/4166 ,  A61N5/06

Abstract: A method for treatment of prostate cancer or benign prostate hyperplasia by combination therapy comprising administering to a patient an androgen-deprivation therapy agent and a bacteriochlorophyll derivative followed by photodynamic therapy (PDT) or vascular-targeted photodynamic therapy (VTP).

公开(公告)号：US10081663B2

公开(公告)日：2018-09-25

申请号：US13958277

申请日：2013-08-02

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Lea Eisenbach ,  Yosi Gozlan ,  Esther Tzehoval

IPC: C12N15/12 ,  C12N15/63 ,  C12N15/85 ,  C12N5/16 ,  C07K14/705 ,  C07K14/725 ,  C12N15/10 ,  A61K35/17

CPC classification number: C07K14/70503 ,  A61K35/17 ,  C07K14/7051 ,  C12N15/102

Abstract: The present invention relates to methods and systems for increasing the affinity of a T cell receptor (TCR) to its ligand by subjecting the TCR gene to somatic hypermutation. The present invention further relates to use of affinity maturated TCRs to create T cells reactive against a selected antigen.

公开(公告)号：US10066014B2

公开(公告)日：2018-09-04

申请号：US15116276

申请日：2015-02-05

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Idit Shachar ,  Inbal Binsky ,  Ayelet Marom

IPC: C07K16/28 ,  G01N33/574 ,  C07K16/30 ,  G01N33/50 ,  A61K39/395

Abstract: An isolated antibody comprising an antigen recognition domain which specifically binds CD84 and (i) down regulates the anti-apoptotic activity of stromal cells on chronic lymphocytic leukemia (CLL) cells; and/or (ii) induces mobilization of CLL cells from the bone marrow. Also provided are antibodies comprising antigen recognition domains comprising complementarity determining regions as indicated and uses thereof.

公开(公告)号：US20180200300A1

公开(公告)日：2018-07-19

申请号：US15873943

申请日：2018-01-18

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Yair REISNER ,  Esther BACHAR-LUSTIG ,  Shlomit REICH-ZELIGER

IPC: A61K35/17 ,  C07K16/28 ,  A61P35/00 ,  A61K35/28 ,  A61K39/395

CPC classification number: A61K35/17 ,  A61K35/28 ,  A61K39/39566 ,  A61P35/00 ,  C07K16/2812 ,  C07K16/2815

Abstract: A method of transplantation is disclosed. The method comprising administering to a subject in need of transplantation of cells in suspension, a therapeutically effective amount of tolerance inducing anti-third party cytotoxic T-lymphocytes (CTLs), wherein the tolerance inducing anti-third party CTLs are generated by directing T-lymphocytes of a donor against a third party antigen or antigens, the tolerance inducing anti-third party CTLs being substantially depleted of T-lymphocytes capable of developing into alloreactive CTLs, and wherein the tolerance inducing anti-third party CTLs do not comprise cells having a central memory T-lymphocyte (Tcm) phenotype, wherein the cells in suspension comprise non-hematopoietic cells or hematopoietic cells which are not stem cells. Methods of treating and kits are also provided.